Drug Patents owned by Biogen Inc

1. List of Tecfidera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399514 BIOGEN INC Treatment for multiple sclerosis
Feb, 2028

(4 years from now)

US10391160 BIOGEN INC Dimethyl fumarate and vaccination regimens
Mar, 2035

(12 years from now)

US10994003 BIOGEN INC Dimethyl fumarate and vaccination regimens
Mar, 2035

(12 years from now)

US10555993 BIOGEN INC Dimethyl fumarate and vaccination regimens
Mar, 2035

(12 years from now)

US11129806 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US10959972 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US11246850 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US11007166 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

US11007167 BIOGEN INC Methods of treating multiple sclerosis
Nov, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
M Feb 5, 2023

Drugs and Companies using DIMETHYL FUMARATE ingredient

Market Authorisation Date: 27 March, 2013

Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of TECFIDERA before it's patent expiration?
More Information on Dosage

TECFIDERA family patents

21

United States

7

Australia

6

China

4

Morocco

4

Japan

4

European Union

2

Korea, Republic of

2

Canada

2

Israel

2

Mexico

2

EA

1

South Africa

1

New Zealand

2. List of Vumerity drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8669281 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

US10080733 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9090558 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

Drugs and Companies using DIROXIMEL FUMARATE ingredient

Market Authorisation Date: 29 October, 2019

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of VUMERITY before it's patent expiration?
More Information on Dosage

VUMERITY family patents

18

United States

4

Singapore

4

New Zealand

3

Australia

3

Canada

2

Korea, Republic of

2

Lithuania

2

Israel

2

Japan

2

Hungary

2

China

2

EA

2

European Union

1

Hong Kong

1

RS

1

Brazil

1

Poland

1

Ukraine

1

Spain

1

Cyprus

1

Mexico

1

Slovenia

1

Portugal

1

Croatia

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic